REGENXBIO to Present at Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announces participation in upcoming virtual investor conferences. Key events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 12, 2020, at 8:45 a.m. ET, and the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 2:00 p.m. ET. Live webcasts will be available on REGENXBIO's website, with archived replays accessible for approximately 30 days post-presentation. The company focuses on gene therapy and has a broad pipeline utilizing its proprietary NAV Technology Platform.

ROCKVILLE, Md., Nov. 5, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced it will present at the following November investor conferences, which will each be held in a virtual meeting format:

29^th Annual Credit Suisse Virtual Healthcare Conference
Date: Thursday, November 12, 2020
Presentation: Thursday, November 12, 2020 at 8:45 a.m. ET

Barclays Gene Editing & Gene Therapy Summit
Date: Monday, November 16, 2020
Presentation: Monday, November 16, 2020 at 2:00 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of each webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301167441.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO presenting at the Credit Suisse Virtual Healthcare Conference?

REGENXBIO will present on November 12, 2020, at 8:45 a.m. ET.

What is the date of the Barclays Gene Editing & Gene Therapy Summit for REGENXBIO?

REGENXBIO's presentation at the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 16, 2020, at 2:00 p.m. ET.

How can I access the live webcast of REGENXBIO's presentations?

Live webcasts can be accessed through the Investors section of REGENXBIO's website.

Will REGENXBIO's presentation webcasts be available after the events?

Yes, archived replays of each presentation will be available for approximately 30 days after the events.

What technology platform does REGENXBIO utilize for gene therapy?

REGENXBIO uses its proprietary NAV Technology Platform for gene therapy applications.